Vertex Pharmaceuticals Inc (VRTX)
$493.27+2.73%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Best-in-class cystic fibrosis franchise; kidney drug approval due end-2026 could unlock the next chapter.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell dis…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- $114.6B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Vertex Pharmaceuticals Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free